Rezolute reports Q3 EPS (28c) , consensus (28c)

Reports cash, cash equivalents and investments in marketable debt securities totaled $106.9M as of September 30 compared to $118.4M as of June 30. “We are on track to commence our Phase 3 study for RZ358 to treat congenital hyperinsulinism prior to year-end and are delighted to have recently obtained PRIME eligibility from the European Medicines Agency for this indication,” said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute. “We also anticipate completing enrollment this quarter for our ongoing Phase 2 study of RZ402 for the treatment of diabetic macular edema and plan to provide an update on the study prior to year end.” Clinical Highlights: RZ358, a monoclonal antibody for the treatment of hyperinsulinism Received EMA priority medicines, PRIME, designation for the treatment of congenital hyperinsulinism,cHI, from the European Medicines Agency